Effect of Amlodipine versus Bisoprolol on Hypertensive Patients with End-stage Renal Disease on Maintenance Hemodialysis.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201909547623017

Enrollment

Registered

2019-09-16

Start date

2019-08-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Disease

Interventions

Amlodipine

Bisoprolol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age 18-80. Male or female patients. On maintenance hemodialysis 3 times weekly for at least 3 months. Hypertensive as determined by predialytic BP > 140/ 90, post-dialytic > 130/80, home- measured BP >140/90 and/or on antihypertensive medication.

Exclusion criteria

Exclusion criteria: History of malignancy. • History of significant valvular heart disease. • Chronic congestive heart failure. • History of coronary artery disease. • Ongoing atrial fibrillation. • Known drug abuse. • Known contraindication to Bisoprolol or Amlodipine. • History of MI • History of stroke

Design outcomes

Primary

Measure	Time frame
Between-group differences in change from baseline (CFB) to 6 months in LVMI.	—

Secondary

Measure	Time frame
Between-group differences in CFB to 6 months in ADMA serum blood level.	—

Countries

Egypt

Contacts

Public ContactAhmed Youssef

Teaching Assistant Faculty of pharmacy Alexandria University

ahmed_youssef@alexu.edu.eg201067676798

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026